Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Therapy

The role of liquid biopsies to manage and predict PRRT for NETs

Nature Reviews Gastroenterology & Hepatology volume 14, pages 331–332 (2017)Cite this article

Subjects

Patients with neuroendocrine tumours are increasingly treated with peptide receptor radionuclide therapy. However, tumour somatostatin receptor expression evaluation cannot accurately predict who will respond to therapy. Additional criteria to identify which patients are most likely to respond and those who will develop radiation-associated sequelae are critical requirements.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Towards precision PRRT for neuroendocrine tumours.

References

  1. Strosberg, J. et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135 (2017).

    Article  CAS  Google Scholar 

  2. Oberg, K. et al. Biomarkers for neuroendocrine tumor disease: a Delphic consensus assessment of multianalytes, genomics, circulating cells and monoanalytes. Lancet Oncol. 16, e435046 (2015).

    Article  Google Scholar 

  3. Kwekkeboom, D. J. et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 26, 2124–2130 (2008).

    Article  CAS  Google Scholar 

  4. Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514–523 (2011).

    Article  CAS  Google Scholar 

  5. Ezziddin, S. et al. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with 177Lu-octreotate. J. Nucl. Med. 52, 1197–1203 (2011).

    Article  Google Scholar 

  6. Kwekkeboom, D. J. et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr. Relat. Cancer. 17, R53–R73 (2010).

    Article  CAS  Google Scholar 

  7. Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501–513 (2011).

    Article  CAS  Google Scholar 

  8. Bodei, L. et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging 43, 839–851 (2016).

    Article  CAS  Google Scholar 

  9. Modlin, I., Drozdov, I. & Kidd, M. The Identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS ONE 8, e63364 (2013).

    Article  CAS  Google Scholar 

  10. Kidd, M., Drozdov, I. & Modlin, I. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr. Relat. Cancer. 22, 561–575 (2015).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are indebted to L. Bodei, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, USA, for meticulous analysis of the manuscript and providing thoughtful commentary and suggestions.

Author information

Authors and Affiliations

  1. Wren Laboratories, 35 NE Industrial Road, Branford, 06405, Connecticut, USA

    Mark Kidd

  2. Department of Surgery, Yale University School of Medicine, 310 Cedar Street, New Haven, 06510, Connecticut, USA

    Irvin M. Modlin

Authors
  1. Mark Kidd
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Irvin M. Modlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Kidd.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kidd, M., Modlin, I. The role of liquid biopsies to manage and predict PRRT for NETs. Nat Rev Gastroenterol Hepatol 14, 331–332 (2017). https://doi.org/10.1038/nrgastro.2017.26

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2017.26

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing